Crossmark

Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

Crossref DOI link: https://doi.org/10.1038/s41443-022-00568-2

Published Online: 2022-05-05

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schifano, Nicolò https://orcid.org/0000-0003-4828-4316
Capogrosso, Paolo https://orcid.org/0000-0003-2347-9504
Boeri, Luca https://orcid.org/0000-0003-0040-784X
Fallara, Giuseppe

Chiappini, Stefania

Rewhorn, Matthew

Cakir, Omer Onur https://orcid.org/0000-0001-7499-7227
Harvey, Hannah

Castiglione, Fabio

Alnajjar, Hussain M.

Muneer, Asif

Deho’, Federico

Schifano, Fabrizio

Montorsi, Francesco

Salonia, Andrea https://orcid.org/0000-0002-0595-7165
License Information

Text and Data Mining valid from 2022-05-05

Version of Record valid from 2022-05-05
More Information

Article History

Received: 5 April 2021

Revised: 22 January 2022

Accepted: 22 March 2022

First Online: 5 May 2022

Competing interests

: FS is a member of the EMA Advisory board (Psychiatry). No further conflicts of interest are here declared.

Document is current

Any future updates will be listed below